Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform

Table 4

Central macular thickness at baseline and 12 months in 37 eyes with macular edema secondary to retinal vein occlusion treated with DEX implant and/or ranibizumab.

	RVO		CRVO		BRVO
	Baseline	12 M	Baseline	12 M	Baseline	12 M
Mean	436.3 ± 135.5	322.2 ± 71.69	478.9 ± 151.5	342 ± 90.55	400.1 ± 111.5	312.2 ± 57.22
Min–Max	294.6–761.9	226.3–483.1	310.7–761.9	226.3–483.1	294.6–711.6	251.7–461
		<0.0001		<0.0043		<0.0072